Metformin and Polycystic Ovary Syndrome
Abstract
The polycystic ovary syndrome (PCOS), one of the most common causes of infertility due to anovulation, affects 4-7%
of women). Etiology of PCOS remains largely unknown, familial aggregation of cases suggests genetic susceptibility to the
disorder. Though genes involved remain unknown, recent evidence points to a gene of the insulin receptor .Genes implicated in
ovarian follicular development may also play a role. A fundamental aspect of the syndrome seems to be a defect in insulin
metabolism. There is consistent evidence that increase of body weight may favour a more severe hyperandrogenism.
Treatment of PCOS has been mostly symptomatic. Only recently has the use of insulinomimetic or insulin sensitizing agents
provided an option to treat the presumed underlying cause of this disorder, which is insulin resistance. Metformin appears to
improve risk factors for cardiovascular disease in diabetic and non-diabetic patients, indicating that its use could be associated
with a reduction in coronary heart disease in patients with PCOS. The use of metformin in hyperinsulinemic women with PCOS
improved the lipid profile, including decreases in total cholesterol, low density lipoprotein cholesterol, and triglyceride
concentration.
of women). Etiology of PCOS remains largely unknown, familial aggregation of cases suggests genetic susceptibility to the
disorder. Though genes involved remain unknown, recent evidence points to a gene of the insulin receptor .Genes implicated in
ovarian follicular development may also play a role. A fundamental aspect of the syndrome seems to be a defect in insulin
metabolism. There is consistent evidence that increase of body weight may favour a more severe hyperandrogenism.
Treatment of PCOS has been mostly symptomatic. Only recently has the use of insulinomimetic or insulin sensitizing agents
provided an option to treat the presumed underlying cause of this disorder, which is insulin resistance. Metformin appears to
improve risk factors for cardiovascular disease in diabetic and non-diabetic patients, indicating that its use could be associated
with a reduction in coronary heart disease in patients with PCOS. The use of metformin in hyperinsulinemic women with PCOS
improved the lipid profile, including decreases in total cholesterol, low density lipoprotein cholesterol, and triglyceride
concentration.
Yousef, M., & Omran, S. (2007). Metformin and Polycystic Ovary Syndrome. International Journal of Health Sciences, 1(1). Retrieved from https://pub.qu.edu.sa/index.php/journal/article/view/114
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Copyright and license info is not available